Amgen Inc.NASDAQ: AMGN

TEZSPIRE® delivered histologic remission and symptom improvement in eosinophilic esophagitis

· Issued by Amgen Inc. via PR Newswire

Summary by 6ix AI

Amgen and AstraZeneca reported full results from the Phase 3 (late-stage) CROSSING trial. The companies say TEZSPIRE (tezepelumab-ekko) showed statistically significant improvements at week 24, sustained through week 52, in adolescents and adults with symptomatic, uncontrolled eosinophilic esophagitis (EoE), a condition affecting the esophagus.

Key details

  • The trial tested TEZSPIRE at 210 mg and 420 mg, given by injection under the skin every four weeks.
  • Histologic remission, meaning remission seen in tissue samples, was reached by 64.8% of patients on the 210 mg dose and 68.9% on the 420 mg dose at week 24, compared with 3.5% of patients on placebo.
  • Symptom improvements versus placebo at week 24 were sustained through week 52.
  • At week 52, TEZSPIRE achieved statistically significant total endoscopic remission versus placebo, meaning no visible inflammation or fibrosis (scarring) when the esophagus was viewed with a camera.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/tezspirer-delivered-histologic-remission-and-symptom-improvement-in-eosinophilic-esophagitis-1

Watch Amgen's latest callAmgen (NASDAQ:AMGN) Q2 2026 Earnings Call · Replay · Aug 4Read the transcript of Amgen (NASDAQ:AMGN) Q2 2026 Earnings Call

Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52

Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at Week 52

THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52 in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis (EoE).1,2 

CROSSING evaluated TEZSPIRE 210 mg and 420 mg administered subcutaneously every four weeks. Treatment with TEZSPIRE achieved histologic remission for 64.8% (210 mg dose) and 68.9% (420 mg dose) of patients at week 24, compared to 3.5% of patients on placebo (p

Amgen Inc. on 6ix

Earlier from Amgen

Later from Amgen

All Amgen news releases